Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Disease

  • J. R. Passweg
  • A. Gratwohl
  • A. Tyndall
Conference paper
Part of the Ernst Schering Research Foundation Workshop Supplement book series (SCHERING FOUND, volume 7)

Abstract

Five years ago the concept of immunoablation with hematopoietic stem cell transplantation was still being discussed as a treatment option for severe autoimmune disease [1]. This has been preceded by data from animal models supporting such a concept [2]. By the end of 1999, data on 250 patients have been reported, with enough experience to say that in selected cases, an acceptable risk/benefit ratio exists to justify the commencement of prospective, comparative randomized trials to determine the place, if any, of such an expensive and toxic procedure in the treatment of severe autoimmune disease.

Keywords

Toxicity Arthritis Leukemia Creatinine Anemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Marmont A, Gratwohl A, Vischer T, Tyndall A (1995) Haemopoietic precursor cell transplants for autoimmune disease. Lancet 345:978CrossRefGoogle Scholar
  2. 2.
    Van Bekkum DW (1993) BMT in experimental autoimmune diseases. Bone Marrow Transplant 11:183–187PubMedGoogle Scholar
  3. 3.
    Marmont AM (1998) Stem cell transplantation for severe autoimmune disease: progress and problems. Haematologica 83:733–744PubMedGoogle Scholar
  4. 4.
    Guillaume T, Rubinstein DB, Symann M (1998) Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 92:147–190Google Scholar
  5. 5.
    Tyndall A, Fassas A, Passweg J et al (1999) Autologous haematopoietic stem cell transplants for autoimmune disease- feasibility and transplant related mortality. Bone Marrow Transplant 24:729–734PubMedCrossRefGoogle Scholar
  6. 6.
    Tyndall A, Gratwohl A (1997) Blood and marrow stem cell transplants in autoimmune disease. A consensus statement on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Br J Rheumatol 36:390–392PubMedCrossRefGoogle Scholar
  7. 7.
    Fassas A, Anagnostopoulos A, Kazis A et al (2000) Autologous stem cell transplantation in progressive multiple sclerosis — an interim analysis on efficacy. J Clin Immunol 20:24–30PubMedCrossRefGoogle Scholar
  8. 8.
    McSweeney P, Furst D, West S (1999) High-dose immunosuppressive therapy for rheumatoid arthritis: some answers, more questions. Arthritis Rheum 42:2269–2274PubMedCrossRefGoogle Scholar
  9. 9.
    Breban M, Dougados M, Picard F et al (1999) Intensified-dose (4 g/m2) cyclophosphamide and granulocyte colony- stimulating factor administration for hematopoietic stem cell mobilisation in refractory rheumatoid arthritis. Arthritis Rheum 42:2275–2280PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • J. R. Passweg
  • A. Gratwohl
  • A. Tyndall

There are no affiliations available

Personalised recommendations